



NEW SERIES: Making basic science relevant

WITH THE article by Hassenbusch and colleagues, the *Cleveland Clinic Journal of Medicine* inaugurates a new series, "Bench to Bedside." "Bench to Bedside" will address issues in basic science that are relevant to current or future practice of medicine.

■ See Hassenbusch and associates (pp 513–520).

Articles will range from basic laboratory studies that can be translated into clinical practice to reviews of the basic science of current treatment modalities. The objective will be to provide insight and improved understanding of current and future treatment modalities.

The data gathered by Hassenbusch and associates show how the results of basic animal research can be applied directly to clinical trials that lead to improved

patient care. The authors describe the animal studies in detail, but also explain how they used the results to develop a clinical protocol.

Another contribution slated for this series will review the rationale for decreased dietary protein intake for patients with chronic renal failure, and advise on how to apply these data to the clinical setting. Also coming up is an article that reviews the use of angiotensin-converting enzyme inhibitors to slow the progression of renal failure in diabetic nephropathy and other forms of progressive renal disease; the authors will provide both experimental background and data from human trials.

BEN H. BROUHARD, MD
Department of Heart and Hypertension Research
Research Institute of the Cleveland Clinic
The Cleveland Clinic Foundation